I agreed with that statement, but from the perspective that the FDA should drop its regulatory capture activities, and increase that 1% to a bigger sampling N. That is, they're focusing their efforts on the wrong problems.

The problems in the article amounts to fraud. Police that and let people decide what they want about what they're seeking.